NYSEAMERICAN:NSPR - InspireMD Stock Price, Price Target & More

$1.30 +0.04 (+3.17 %)

(As of 04/19/2018 11:31 AM ET)

Previous Close$1.26

Today's Range$1.21 - $1.38

52-Week Range$0.70 - $28.70

Volume417,236 shs

Average Volume676,143 shs

Market Capitalization$7.11 million

P/E RatioN/A

Dividend YieldN/A

Beta2.61

About InspireMD (NYSEAMERICAN:NSPR)

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

Receive NSPR News and Ratings via Email

Sign-up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Appliances & Equipment

Sub-IndustryN/A

SectorMedical

SymbolNYSEAMERICAN:NSPR

CUSIPN/A

Webwww.inspiremd.com

Phone+1-857-4536553

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins-179.74%

Return on Equity-720.33%

Return on Assets-90.96%

Miscellaneous

EmployeesN/A

Outstanding Shares3,000,000

How to Become a New Pot Stock Millionaire

InspireMD (NYSEAMERICAN:NSPR) Frequently Asked Questions

What is InspireMD's stock symbol?

InspireMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NSPR."

When did InspireMD's stock split? How did InspireMD's stock split work?

InspireMD's stock reverse split on Thursday, February 8th 2018. The 1-35 reverse split was announced on Wednesday, February 7th 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 7th 2018. An investor that had 100 shares of InspireMD stock prior to the reverse split would have 3 shares after the split.

How were InspireMD's earnings last quarter?

InspireMD (NYSEAMERICAN:NSPR) announced its quarterly earnings data on Wednesday, February, 14th. The medical equipment provider reported ($7.38) EPS for the quarter. The medical equipment provider had revenue of $0.83 million for the quarter. InspireMD had a negative return on equity of 720.33% and a negative net margin of 179.74%. View InspireMD's Earnings History.

Are investors shorting InspireMD?

InspireMD saw a increase in short interest in March. As of March 29th, there was short interest totalling 291,391 shares, an increase of 66.4% from the March 15th total of 175,161 shares. Based on an average trading volume of 1,535,386 shares, the days-to-cover ratio is presently 0.2 days. Currently, 5.1% of the shares of the stock are short sold.

Who are some of InspireMD's key competitors?

Some companies that are related to InspireMD include Vialogy (NIPT), Vernalis (VNLPY), CHF Solutions (CHFS), OHR Pharmaceutical (OHRP), Windtree Therapeutics (WINT), Lidco Group (LID), Alliqua BioMedical (ALQA), Evgen Pharma (EVG), Acura Pharmaceuticals (ACUR), Neurometrix (NURO), OpGen (OPGN), EpiCept (IMNP), Phytopharm (IXI), Proteome Sciences (PRM), Argos Therapeutics (ARGS), EyeGate Pharma (EYEG), Auris Medical (EARS) and SenesTech (SNES).

Who are InspireMD's key executives?

InspireMD's management team includes the folowing people:

Dr. James J. Barry Ph.D., Pres, CEO & Director (Age 59)
Mr. Craig Shore, CFO, Chief Admin. Officer, Treasurer & Sec. (Age 57)
Mr. Agustin V. Gago, Exec. VP & Chief Commercial Officer (Age 58)
Dr. Sol J. Barer, Special Advisor to the Board (Age 71)
Mr. Benzi Spector, Head of R&D and Operations

Has InspireMD been receiving favorable news coverage?

Media coverage about NSPR stock has been trending somewhat positive recently, according to Accern. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. InspireMD earned a coverage optimism score of 0.06 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of InspireMD?

Shares of NSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InspireMD's stock price today?

One share of NSPR stock can currently be purchased for approximately $1.34.

How big of a company is InspireMD?

InspireMD has a market capitalization of $7.11 million.

How can I contact InspireMD?

InspireMD's mailing address is 4 Menorat Hamaor St., TEL AVIV-YAFO, MA 6744832, Israel. The medical equipment provider can be reached via phone at +1-857-4536553.

MarketBeat Community Rating for InspireMD (NSPR)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		88 (Vote Outperform)
Underperform Votes:		84 (Vote Underperform)
Total Votes:		172

MarketBeat's community ratings are surveys of what our community members think about InspireMD and other stocks. Vote "Outperform" if you believe NSPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

InspireMD (NYSEAMERICAN:NSPR) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Details

(Data available from 4/19/2016 forward)

InspireMD (NYSEAMERICAN:NSPR) Earnings History and Estimates Chart

Earnings by Quarter for InspireMD (NYSEAMERICAN:NSPR)

InspireMD (NYSEAMERICAN NSPR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/14/2018	Q4 2017		($7.38)		$0.83 million	View	N/A
11/7/2017	Q3 2017		($6.65)		$0.72 million	View	N/A
8/8/2017	Q2 2017		($7.35)		$0.64 million	View	N/A
5/9/2017	Q1 2017		($28.35)		$0.57 million	View	N/A
2/16/2017	Q4 2016		($30.80)		$0.32 million	View	N/A
11/14/2016	Q3 2016		($30.10)		$0.47 million	View	N/A
8/9/2016	Q216	($5.95)	($6.65)	$0.80 million	$0.54 million	View	N/A
5/10/2016	Q1 2016	($306.25)	($280.00)	$0.70 million	$0.56 million	View	N/A
3/28/2016	Q415	($16.10)	($12.95)	$0.80 million	$0.52 million	View	N/A
11/10/2015	Q315	($17.50)	($15.75)		$0.63 million	View	Listen
8/5/2015	Q215	($1.75)	($1.75)		$0.69 million	View	N/A
5/11/2015	Q214	($1.75)	($2.80)	$0.90 million	$0.48 million	View	Listen
3/12/2015	Q4 2014	($5.95)	($4.20)	$0.07 million	$0.87 million	View	N/A
11/12/2014	Q3 2014	($1,925.00)	($1,750.00)	$0.40 million	$0.27 million	View	N/A
7/23/2014	Q2 2014		($1,925.00)	$1.75 million	$0.19 million	View	N/A
5/7/2014	Q1 2014	($5.25)	($6.30)	$1.65 million	$1.48 million	View	N/A
2/26/2014	Q4 2013		($1,400.00)	$1.90 million	$1.55 million	View	N/A
11/11/2013	Q114	($3.85)	($3.15)	$1.60 million	$2.30 million	View	N/A
9/17/2013	Q413	($4.55)	($3.50)	$1.50 million	$1.50 million	View	N/A
5/8/2013	Q313		($9.45)	$1.14 million	$1.51 million	View	N/A
2/4/2013	Q4 2012		$962.50			View	N/A
11/2/2012	Q3 2012		($3,850.00)			View	N/A
9/12/2012	Q2 2012		($1,750.00)			View	N/A
5/8/2012	Q1 2012		($1,750.00)			View	N/A

(Earnings results data provided by Zacks Investment Research)

InspireMD (NYSEAMERICAN:NSPR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

InspireMD (NYSEAMERICAN NSPR) Insider Trading and Institutional Ownership History

Insider Trading History for InspireMD (NYSEAMERICAN:NSPR)

InspireMD (NYSEAMERICAN NSPR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/21/2016	Paul Stuka	Director	Buy	127,119	$0.59	$75,000.21
5/29/2014	Eric L Olson	VP	Buy	31,778	$2.55	$81,033.90
5/13/2014	Sol J Barer	Director	Buy	50,000	$2.44	$122,000.00
5/12/2014	Alan Milinazzo	CEO	Buy	7,100	$2.36	$16,756.00
11/26/2013	Asher Holzer	Director	Sell	597,300	$2.64	$1,576,872.00
11/20/2013	Asher Holzer	Director	Sell	1,600	$2.69	$4,304.00
5/31/2013	Sol J Barer	Director	Buy	20,000	$2.26	$45,200.00
5/30/2013	Sol J Barer	Director	Buy	20,000	$2.07	$41,400.00
5/29/2013	Alan Milinazzo	CEO	Buy	15,000	$2.11	$31,650.00
5/29/2013	Sol J Barer	Director	Buy	20,000	$2.09	$41,800.00
5/28/2013	Sol J Barer	Director	Buy	20,000	$2.15	$43,000.00
5/24/2013	Sol J Barer	Director	Buy	20,000	$2.10	$42,000.00
4/25/2013	Sol J Barer	Director	Buy	50,000	$2.00	$100,000.00
4/16/2013	Alan Milinazzo	CEO	Buy	100,000	$2.00	$200,000.00
4/16/2013	Sol J Barer	Director	Buy	750,000	$2.00	$1,500,000.00

(Data available from 1/1/2013 forward)

InspireMD (NYSEAMERICAN NSPR) News Headlines

Source:

Date	Headline
	InspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland feeds.benzinga.com - April 19 at 7:34 AM
	InspireMD (NSPR) Short Interest Up 66.4% in March www.americanbankingnews.com - April 10 at 6:35 PM
	InspireMD (NSPR) Total Q1 Sales to Exceed $1 Million www.streetinsider.com - April 4 at 8:29 AM
	InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million finance.yahoo.com - April 3 at 5:29 PM
	InspireMD reports preliminary Q1 sales seekingalpha.com - April 3 at 10:52 AM
	InspireMD (NSPR) Receives Regulatory Approval for both CGuard EPS and MGuard Prime in Peru www.streetinsider.com - March 29 at 8:35 AM
	Blog Exposure - InspireMD Announced Regulatory Approval for CGuard Embolic Prevention System and MGuard Prime in Peru finance.yahoo.com - March 29 at 8:35 AM
	Mid-Afternoon Market Update: RH Rises On Upbeat Earnings; InspireMD Shares Slide www.nasdaq.com - March 28 at 5:13 PM
	Health Care Sector Update for 03/28/2018: SHPG,APRI,NSPR www.nasdaq.com - March 28 at 8:35 AM
	Mid-Day Market Update: Dow Rises Over 100 Points; InspireMD Shares Spike Higher www.benzinga.com - March 28 at 8:35 AM
	InspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock finance.yahoo.com - March 28 at 8:35 AM
	InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Peru finance.yahoo.com - March 27 at 8:36 AM
	InspireMD (NSPR) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - March 21 at 1:18 AM
	InspireMD Inc (NSPR) Sees Significant Growth in Short Interest www.americanbankingnews.com - March 9 at 6:04 PM
	With A -53.98% Earnings Drop, Is InspireMD Inc’s (NYSEMKT:NSPR) Performance A Concern? finance.yahoo.com - March 8 at 6:30 PM
	InspireMD Announces First Patient Treated with CGuard™ EPS in India finance.yahoo.com - March 5 at 8:28 AM
	InspireMD Announces Expansion of its Distribution Network finance.yahoo.com - March 1 at 8:20 AM
	InspireMD Inc (NSPR) Short Interest Down 96.8% in February www.americanbankingnews.com - February 28 at 1:56 AM
	InspireMD, Inc. Announces Pricing of Public Offering of Common Stock finance.yahoo.com - February 27 at 8:26 AM
	InspireMD, Inc. Announces Proposed Public Offering of Common Stock finance.yahoo.com - February 26 at 5:40 PM
	InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea finance.yahoo.com - February 22 at 5:33 PM
	InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India finance.yahoo.com - February 20 at 5:41 PM
	InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year finance.yahoo.com - February 14 at 9:49 AM
	Today’s Research Reports on Trending Tickers: Eli Lilly and Company and InspireMD finance.yahoo.com - February 10 at 9:42 AM
	InspireMD Inc (NSPR) Short Interest Update www.americanbankingnews.com - February 9 at 8:28 PM
	InspireMD (NSPR) Plans 1-for-35 Reverse Stock Split www.streetinsider.com - February 8 at 8:15 AM
	InspireMD Announces 1-for-35 Reverse Stock Split finance.yahoo.com - February 8 at 8:15 AM
	InspireMD, CGuard is Ramping up Revenues, Business Outlook, and Analysts Review finance.yahoo.com - February 1 at 9:57 AM
	InspireMD's CGuard Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists finance.yahoo.com - January 31 at 10:17 AM
	InspireMD’s CGuard™ Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons finance.yahoo.com - January 30 at 10:18 AM
	InspireMD’s CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018 finance.yahoo.com - January 26 at 3:47 PM
	InspireMD Inc (NSPR) Short Interest Up 26.6% in January www.americanbankingnews.com - January 24 at 5:40 PM
	InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent finance.yahoo.com - January 19 at 11:41 AM
	InspireMD Inc (NSPR) Sees Large Growth in Short Interest www.americanbankingnews.com - January 10 at 6:06 PM
	Today’s Research Reports on Trending Tickers: Akers Biosciences and InspireMD, Inc. finance.yahoo.com - January 10 at 10:20 AM
	InspireMD (NSPR) Reports Approval of CGuard EPS in India and Agreement with Leading Indian Medical Device Distributor www.streetinsider.com - January 5 at 4:23 PM
	techstockinsider.com: 2 Medical Technology Stocks That Have Investors' Attention www.finanznachrichten.de - January 5 at 4:23 PM
	2 Medical Technology Stocks That Have Investors' Attention finance.yahoo.com - January 3 at 4:42 PM
	InspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting finance.yahoo.com - January 3 at 4:42 PM
	InspireMD Announces Regulatory Approval of CGuard EPS in India; Signs Agreement with Leading Indian Medical Device Distributor finance.yahoo.com - January 3 at 9:32 AM
	InspireMD Inc (NSPR) Sees Significant Increase in Short Interest www.americanbankingnews.com - December 27 at 6:38 PM
	InspireMD’s CGuard™ Embolic Prevention System Once Again Featured in a Successful Live Clinical Case at Leading Industry Conference finance.yahoo.com - December 18 at 4:38 PM
	InspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017 finance.yahoo.com - December 7 at 4:56 PM
	Five Innovative Biotech Stocks for the New Year www.prnewswire.com - December 7 at 10:37 AM
	InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS finance.yahoo.com - December 5 at 4:37 PM

InspireMD (NYSEAMERICAN:NSPR) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

InspireMD (NYSEAMERICAN:NSPR) Income Statement, Balance Sheet and Cash Flow Statement

InspireMD (NYSEAMERICAN NSPR) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff